{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:20:06Z","timestamp":1770960006124,"version":"3.50.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Thrombotic microangiopathy (TMA) on kidney biopsy is a pattern of endothelial injury commonly seen in malignant hypertension (mHTN), but treatment strategies are not well established.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril\/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy for patients with mHTN-associated TMA.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This single-center cohort study enrolled consecutive patients in China diagnosed with mHTN-associated TMA through kidney biopsy from January 2008 to June 2023. Follow-up was conducted until the conclusion of the study period. Data were analyzed in September 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Treatment with sacubitril\/valsartan or ACEI\/ARBs during hospitalization and after discharge.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was a composite of kidney recovery: a 50% decrease in serum creatinine level, decrease in serum creatinine levels to the reference range, or kidney survival free from dialysis for more than 1 month. The secondary and tertiary outcomes were a 15% increase in the estimated glomerular filtration rate (eGFR) relative to baseline and kidney survival free from dialysis, respectively. Propensity score matching (PSM) and Cox proportional hazards regression analysis were used to evaluate the association between sacubitril\/valsartan and ACEI\/ARB therapy with kidney recovery outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril\/valsartan and 151 (69.6%) received ACEI\/ARBs at baseline. Sacubitril\/valsartan treatment was associated with shorter time to the primary outcome compared with ACEI\/ARB treatment (20 of 63 [31.7%] vs 38 of 117 [32.5%]; adjusted hazard ratio [aHR], 1.85; 95% CI, 1.05-3.23). Sacubitril\/valsartan treatment was independently associated with shorter time to a 15% increase in eGFR (15 of 46 [32.6%] vs 46 of 83 [55.4%]; aHR, 2.13; 95% CI, 1.09-4.17) and kidney survival free from dialysis (11 of 23 [47.8%] vs 16 of 57 [28.1%]; aHR, 2.63; 95% CI, 1.15-5.88) compared with ACEI\/ARB treatment. These differences remained significant in the PSM comparison.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, sacubitril\/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI\/ARB treatment. The findings suggested that sacubitril\/valsartan could be a superior therapeutic approach for managing this serious condition in terms of kidney recovery.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.32862","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:13:29Z","timestamp":1726154009000},"page":"e2432862","source":"Crossref","is-referenced-by-count":10,"title":["Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor\/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy"],"prefix":"10.1001","volume":"7","author":[{"given":"Jianbo","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China"},{"name":"Department of Nephrology, Jieyang People\u2019s Hospital, Jieyang, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingji","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Guangzhou First People\u2019s Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Guangzhou First People\u2019s Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Guangzhou First People\u2019s Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Guangzhou First People\u2019s Hospital, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"7","key":"zoi240991r1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023397","article-title":"Malignant hypertension: current perspectives and challenges.","volume":"11","author":"Boulestreau","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"zoi240991r2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy.","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"issue":"5","key":"zoi240991r3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","article-title":"Thrombotic microangiopathy in patients with malignant hypertension.","volume":"38","author":"Cavero","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"zoi240991r4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review.","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"zoi240991r5","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","article-title":"Thrombotic microangiopathy and associated renal disorders.","volume":"27","author":"Barbour","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"zoi240991r6","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1093\/ndt\/gfq143","article-title":"Long-term renal survival in malignant hypertension.","volume":"25","author":"Gonz\u00e1lez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"zoi240991r7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH674>3.0.CO;2-Q","article-title":"Malignant hypertension\u2014the role of the paracrine renin-angiotensin system.","volume":"192","author":"Fleming","year":"2000","journal-title":"J Pathol"},{"issue":"1","key":"zoi240991r8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ehjcvp\/pvy032","article-title":"ESC Council on hypertension position document on the management of hypertensive emergencies.","volume":"5","author":"van den Born","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"zoi240991r9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.amjhyper.2007.02.018","article-title":"The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension.","volume":"20","author":"van den Born","year":"2007","journal-title":"Am J Hypertens"},{"issue":"6","key":"zoi240991r10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines.","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"7","key":"zoi240991r11","article-title":"Acute severe hypertension.","volume":"382","author":"Parmar","year":"2020","journal-title":"N Engl J Med"},{"issue":"9722","key":"zoi240991r12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"zoi240991r13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240991r14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","article-title":"Renal protection in chronic heart failure: focus on sacubitril\/valsartan.","volume":"7","author":"Pontremoli","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"zoi240991r15","article-title":"The efficacy and safety of sacubitril\/valsartan in chronic kidney disease: a systematic review and meta-analysis.","author":"Zhou","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"zoi240991r16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1681\/ASN.V91133","article-title":"Malignant hypertension and hypertensive emergencies.","volume":"9","author":"Kitiyakara","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"zoi240991r17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities.","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"zoi240991r18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"zoi240991r19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"19","key":"zoi240991r20","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"2","key":"zoi240991r21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12350-017-1012-y","article-title":"Reducing bias using propensity score matching.","volume":"25","author":"Morgan","year":"2018","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"zoi240991r22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"issue":"7","key":"zoi240991r23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ndt\/gfaa280","article-title":"Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis.","volume":"36","author":"Zhang","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"zoi240991r24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jash.2015.12.007","article-title":"The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy.","volume":"10","author":"Mathew","year":"2016","journal-title":"J Am Soc Hypertens"},{"issue":"2-3","key":"zoi240991r25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/080370500453429","article-title":"Angiotensin-converting enzyme gene I\/D polymorphism in malignant hypertension.","volume":"9","author":"Stefansson","year":"2000","journal-title":"Blood Press"},{"issue":"11","key":"zoi240991r26","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1097\/HJH.0000000000002547","article-title":"The pharmacological management of malignant hypertension.","volume":"38","author":"Gosse","year":"2020","journal-title":"J Hypertens"},{"issue":"6","key":"zoi240991r27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"13","key":"zoi240991r28","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction.","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"zoi240991r29","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials.","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"8","key":"zoi240991r30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11739-019-02111-6","article-title":"Renal effects of sacubitril\/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.","volume":"14","author":"Spannella","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"4","key":"zoi240991r31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"zoi240991r32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides.","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi240991r33","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/ijms20112629","article-title":"Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications.","volume":"20","author":"Tanase","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"15","key":"zoi240991r34","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease.","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"zoi240991r35","first-page":"5473","article-title":"LCZ696 (sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.","volume":"9","author":"Jing","year":"2017","journal-title":"Am J Transl Res"},{"issue":"11","key":"zoi240991r36","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823634\/li_2024_oi_240991_1725563644.53764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T15:13:45Z","timestamp":1726154025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.32862","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}